CoChat
Sign Up
Cited by 44

The DOI matches its Crossref record.

Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1

Shoghi, Kooresh I., Xu, Jinbin, Su, Yi, He, June, Rowland, Douglas, Yan, Ying, Garbow, Joel R., Tu, Zhude, Jones, Lynne A., Higashikubo, Ryuji, Wheeler, Kenneth T., Lubet, Ronald A., Mach, Robert H., You, Ming·2013·PLoS ONE
DOI 10.1371/journal.pone.0074188PMC PMC3779213
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0074188

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PET imaging studies with [18F]ISO-1 show a strong correlation between radiotracer uptake and σ2R density in a murine breast cancer model, and an excellent correlation between radiotracer uptake and Ki-67 score in patients with lymphoma, breast, and head & neck cancer.

    “PET imaging studies with a σ2R -selective radiotracer, [18F]ISO-1, have shown a strong correlation between radiotracer uptake and the density of σ2R in a murine model of breast cancer30, and an excellent correlation between radiotracer uptake and Ki-67 score in a mixed population of patients diagnosed with lymphoma, breast, and head & neck cancer31.”

    From Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex (2018) · cites this paper as [30]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 39

  1. WB Eubank, 2005, Evolving role of positron emission tomography in breast cancer imaging, Semin Nucl Med, 35, 84, 10.1053/j.semnuclmed.2004.11.001 · DOI
  2. Kumar R, Alavi A (2004) Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 42: 1113–1122, ix. · DOI
  3. N Avril, 2001, Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis, J Nucl Med, 42, 9
  4. AF Shields, 1998, Imaging proliferation in vivo with [F-18]FLT and positron emission tomography, Nat Med, 4, 1334, 10.1038/3337 · DOI
  5. Mach RH, Zeng C, Hawkins WG (2013) The sigma Receptor: A Novel Protein for the Imaging and Treatment of Cancer. J Med Chem. · DOI
  6. M Loddo, 2009, Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer, Br J Cancer, 100, 959, 10.1038/sj.bjc.6604924 · DOI
  7. Fornace AJ, Fuks Z, Weichselbaum RR, Milas L (2001) Radiation Therapy. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The Molecular Basis of Cancer. Philadelphia, PA: W. B. Saunders Co. 423−466.
  8. I Collins, 2005, Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors, Curr Opin Pharmacol, 5, 366, 10.1016/j.coph.2005.04.009 · DOI
  9. K Strebhardt, 2006, Targeting polo-like kinase 1 for cancer therapy, Nat Rev Cancer, 6, 321, 10.1038/nrc1841 · DOI
  10. T Scholzen, 2000, The Ki-67 protein: from the known and the unknown, J Cell Physiol, 182, 311, 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 · DOI
  11. WT Bem, 1991, Overexpression of sigma receptors in nonneural human tumors, Cancer Res, 51, 6558
  12. RH Mach, 1997, Sigma 2 receptors as potential biomarkers of proliferation in breast cancer, Cancer Res, 57, 156
  13. BJ Vilner, 1995, Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines, Cancer Res, 55, 408
  14. I Al-Nabulsi, 1999, Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells, Br J Cancer, 81, 925, 10.1038/sj.bjc.6690789 · DOI
  15. KT Wheeler, 2000, Sigma-2 receptors as a biomarker of proliferation in solid tumours, Br J Cancer, 82, 1223, 10.1054/bjoc.1999.1067 · DOI · Paper page
  16. Z Tu, 2007, Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography, J Med Chem, 50, 3194, 10.1021/jm0614883 · DOI
  17. Z Tu, 2005, Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer, Nucl Med Biol, 32, 423, 10.1016/j.nucmedbio.2005.03.008 · DOI
  18. H Kashiwagi, 2007, Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy, Mol Cancer, 6, 48, 10.1186/1476-4598-6-48 · DOI
  19. F Dehdashti, 2013, Assessment of cellular proliferation in tumors by PET using 18F-ISO-1, J Nucl Med, 54, 350, 10.2967/jnumed.112.111948 · DOI · Paper page
  20. PM Gullino, 1975, N-nitrosomethylurea as mammary gland carcinogen in rats, J Natl Cancer Inst, 54, 401
  21. C Huggins, 1965, Two principles in endocrine therapy of cancers: hormone deprival and hormone interference, Cancer Res, 25, 1163
  22. RA Lubet, 2005, Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis, Carcinogenesis, 26, 441, 10.1093/carcin/bgh338 · DOI
  23. J Xu, 2005, [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5 -methylbenzamide: A novel sigma-2 receptor probe, Eur J Pharmacol, 525, 8, 10.1016/j.ejphar.2005.09.063 · DOI
  24. G Scatchard, 1949, The attractions of proteins for small molecules and ions, Ann NY Acad Sci, 51, 662, 10.1111/j.1749-6632.1949.tb27297.x · DOI
  25. R Laforest, 2007, Performance evaluation of the microPET (R) - FOCUS-F120, Ieee Transactions on Nuclear Science, 54, 42, 10.1109/TNS.2006.889312 · DOI
  26. YC Tai, 2005, Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging, J Nucl Med, 46, 455
  27. CA Wallen, 1984, Murine mammary tumour cells in vitro. II. Recruitment of quiescent cells, Cell Tissue Kinet, 17, 79
  28. CA Wallen, 1984, Murine mammary tumour cells in vitro. I. The development of a quiescent state, Cell Tissue Kinet, 17, 65
  29. FA Alves, 2004, PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumours, Int J Oral Maxillofac Surg, 33, 593, 10.1016/j.ijom.2004.01.010 · DOI
  30. A van Waarde, 2004, Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study, J Nucl Med, 45, 1939
  31. K Endo, 2006, PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients, Int J Clin Oncol, 11, 286, 10.1007/s10147-006-0595-0 · DOI
  32. E Miele, 2008, Positron Emission Tomography (PET) radiotracers in oncology–utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC), J Exp Clin Cancer Res, 27, 52, 10.1186/1756-9966-27-52 · DOI
  33. EL Rosen, 2007, FDG PET, PET/CT, and breast cancer imaging, Radiographics, 27, S215, 10.1148/rg.27si075517 · DOI
  34. H Sun, 2005, Imaging DNA synthesis in vivo with 18F-FMAU and PET, J Nucl Med, 46, 292
  35. U Haberkorn, 1994, FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models, Nucl Med Biol, 21, 827, 10.1016/0969-8051(94)90162-7 · DOI
  36. K Christov, 2007, Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model, Clin Cancer Res, 13, 5488, 10.1158/1078-0432.CCR-07-0404 · DOI
  37. K Christov, 2000, Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole, Breast Cancer Res Treat, 60, 117, 10.1023/A:1006384026252 · DOI
  38. RA Lubet, 1998, Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model, Carcinogenesis, 19, 1345, 10.1093/carcin/19.8.1345 · DOI
  39. M Dowsett, 2007, Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer, J Natl Cancer Inst, 99, 167, 10.1093/jnci/djk020 · DOI

Cited by

Sorted by citations

Metadata

Authors
Shoghi, K. I., Xu, J., Su, Y., He, J., Rowland, D., Yan, Y., Garbow, J. R., Tu, Z., Jones, L. A., Higashikubo, R., Wheeler, K. T., Lubet, R. A., Mach, R. H., & You, M.
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-09-20
Volume
8
Issue
9
Pages
e74188
ISSN
1932-6203
DOI
10.1371/journal.pone.0074188
PMC
PMC3779213
Cited by
44
References
0
Language
en
Licence
creativecommons.org/publicdomain/zero/1.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review